Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort

Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. To develop models...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2023-12, Vol.24 (12), p.1434-1442
Hauptverfasser: Im, Cindy, Lu, Zhe, Mostoufi-Moab, Sogol, Delaney, Angela, Yu, Lin, Baedke, Jessica L, Han, Yutong, Sapkota, Yadav, Yasui, Yutaka, Chow, Eric J, Howell, Rebecca M, Bhatia, Smita, Hudson, Melissa M, Ness, Kirsten K, Armstrong, Gregory T, Nathan, Paul C, Yuan, Yan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1442
container_issue 12
container_start_page 1434
container_title The lancet oncology
container_volume 24
creator Im, Cindy
Lu, Zhe
Mostoufi-Moab, Sogol
Delaney, Angela
Yu, Lin
Baedke, Jessica L
Han, Yutong
Sapkota, Yadav
Yasui, Yutaka
Chow, Eric J
Howell, Rebecca M
Bhatia, Smita
Hudson, Melissa M
Ness, Kirsten K
Armstrong, Gregory T
Nathan, Paul C
Yuan, Yan
description Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. To develop models to predict age-specific POI risk for the ages of 21–40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included. We evaluated models that used algorithms based on statistical or machine learning to consider all predictors, including cancer treatments. Cross-validated prediction performance metrics (eg, area under the receiver operating characteristic curve [AUROC]) were compared to select the best-performing models. For external validation of the models, we used data from 5-year survivors in the St Jude Lifetime Cohort (SJLIFE) with ovarian status clinically ascertained using hormone measurements (menopause defined by follicle stimulating hormone >30 mIU/mL and oestradiol
doi_str_mv 10.1016/S1470-2045(23)00510-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2891752453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204523005107</els_id><sourcerecordid>2891752453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-fc71914cec35e030829c34b72668375a7fc7e6b64c64c17fde41f696be648b0a3</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhSMEYmYKjwC6EpthEbATJ07YIFSGP1ViUVhbjn099ZDEHduJ1IflXXDTMgs2SJZsX3_n3CufLHtByRtKaP12SxkneUFYdV2UrwmpKMn5o-wylVlesaZ5vJxPyEV2FcIdIZRTUj3NLkre8qImzWX2-yPO2Lv9gGMEOWqYZW-1jNaN4AzIW8zDHpU1VoG34RfsPWqrlvfBaewDGOdT1Q7SH8DN0ls5gh3DZJLG4qgO6Qa9G2_ziH6AMPnZzs6Ho7_a2V7vnNOg5KjQvwMJHvfORzDeDRB3COsHZr0wsD07wDZO-rBMvY3wbdIIG2sw2iGJ3C6ZPMueGNkHfH7eV9nPTzc_1l_yzffPX9cfNrlijMTcKE5byhSqskJSkqZoVcm69EV1U_JK8gRg3dVMpUW50cioqdu6w5o1HZHlKrs--e69u58wRDHYoLDv5YhuCqJoWsqrglVlQl_9g965yY9puiPFkmuRmq6y6kQp70LwaMT5hwUl4pi_WPIXx3BFUYolf8GT7uXZfeoG1A-qv4En4P0JSMnhbNGLsISUQvWootDO_qfFH8MuxBY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2894696268</pqid></control><display><type>article</type><title>Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Im, Cindy ; Lu, Zhe ; Mostoufi-Moab, Sogol ; Delaney, Angela ; Yu, Lin ; Baedke, Jessica L ; Han, Yutong ; Sapkota, Yadav ; Yasui, Yutaka ; Chow, Eric J ; Howell, Rebecca M ; Bhatia, Smita ; Hudson, Melissa M ; Ness, Kirsten K ; Armstrong, Gregory T ; Nathan, Paul C ; Yuan, Yan</creator><creatorcontrib>Im, Cindy ; Lu, Zhe ; Mostoufi-Moab, Sogol ; Delaney, Angela ; Yu, Lin ; Baedke, Jessica L ; Han, Yutong ; Sapkota, Yadav ; Yasui, Yutaka ; Chow, Eric J ; Howell, Rebecca M ; Bhatia, Smita ; Hudson, Melissa M ; Ness, Kirsten K ; Armstrong, Gregory T ; Nathan, Paul C ; Yuan, Yan</creatorcontrib><description>Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. To develop models to predict age-specific POI risk for the ages of 21–40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included. We evaluated models that used algorithms based on statistical or machine learning to consider all predictors, including cancer treatments. Cross-validated prediction performance metrics (eg, area under the receiver operating characteristic curve [AUROC]) were compared to select the best-performing models. For external validation of the models, we used data from 5-year survivors in the St Jude Lifetime Cohort (SJLIFE) with ovarian status clinically ascertained using hormone measurements (menopause defined by follicle stimulating hormone &gt;30 mIU/mL and oestradiol &lt;17 pg/mL) and medical chart or questionnaire review. We also evaluated an SJLIFE-based polygenic risk score for POI among 1985 CCSS survivors with genotype data available. 7891 female CCSS survivors (922 with POI) were included in the development of the POI risk prediction model, and 1349 female SJLIFE survivors (101 with POI) were included in the validation study. Median follow-up from cancer diagnosis was 23·7 years (IQR 18·3–30·0) in CCSS and 15·1 years (10·4–22·9) in SJLIFE. Between the ages of 21 and 40 years, POI prevalence increased from 7·9% (95% CI 7·3–8·5) to 18·6% (17·3–20·0) in CCSS and 7·3% (5·8–8·9) to 14·9% (11·6–19·1) in SJLIFE. Age-specific logistic regression models considering ovarian radiation dosimetry or prescribed pelvic and abdominal radiation dose, along with individual chemotherapy predictors, performed well in CCSS. In the SJLIFE validation, the prescribed radiation dose model performed well (AUROC 0·88–0·95), as did a simpler model that considered any exposures to pelvic or abdominal radiotherapy or alkylators (0·82–0·90). Addition of the polygenic risk predictor significantly improved the average positive predictive value (from 0·76 [95% CI 0·63–0·89] to 0·87 [0·80–0·94]; p=0·029) among CCSS survivors treated with ovarian radiation and chemotherapy. POI risk prediction models using treatment information showed robust prediction performance in adult survivors of childhood cancer. Canadian Institutes of Health Research, US National Cancer Institute.</description><identifier>ISSN: 1470-2045</identifier><identifier>ISSN: 1474-5488</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(23)00510-7</identifier><identifier>PMID: 37972608</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Abdomen ; Adult ; Age ; Age Factors ; Canada ; Cancer Survivors ; Cancer therapies ; Chemotherapy ; Child ; Childhood ; Children ; Diagnosis ; Dosimetry ; Drug dosages ; Female ; Fertility ; Genotypes ; Humans ; Medical diagnosis ; Medical records ; Menopause ; Menstruation ; Neoplasms - drug therapy ; Neoplasms - therapy ; Ovaries ; Patients ; Pediatrics ; Prediction models ; Primary Ovarian Insufficiency - diagnosis ; Primary Ovarian Insufficiency - epidemiology ; Primary Ovarian Insufficiency - etiology ; Questionnaires ; Radiation therapy ; Regression analysis ; Reproductive status ; Risk Factors ; Self report ; Statistical analysis ; Survivor ; Survivors ; Transplants &amp; implants ; Tumors ; Young Adult ; Young adults</subject><ispartof>The lancet oncology, 2023-12, Vol.24 (12), p.1434-1442</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-fc71914cec35e030829c34b72668375a7fc7e6b64c64c17fde41f696be648b0a3</citedby><cites>FETCH-LOGICAL-c440t-fc71914cec35e030829c34b72668375a7fc7e6b64c64c17fde41f696be648b0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2894696268?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37972608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Im, Cindy</creatorcontrib><creatorcontrib>Lu, Zhe</creatorcontrib><creatorcontrib>Mostoufi-Moab, Sogol</creatorcontrib><creatorcontrib>Delaney, Angela</creatorcontrib><creatorcontrib>Yu, Lin</creatorcontrib><creatorcontrib>Baedke, Jessica L</creatorcontrib><creatorcontrib>Han, Yutong</creatorcontrib><creatorcontrib>Sapkota, Yadav</creatorcontrib><creatorcontrib>Yasui, Yutaka</creatorcontrib><creatorcontrib>Chow, Eric J</creatorcontrib><creatorcontrib>Howell, Rebecca M</creatorcontrib><creatorcontrib>Bhatia, Smita</creatorcontrib><creatorcontrib>Hudson, Melissa M</creatorcontrib><creatorcontrib>Ness, Kirsten K</creatorcontrib><creatorcontrib>Armstrong, Gregory T</creatorcontrib><creatorcontrib>Nathan, Paul C</creatorcontrib><creatorcontrib>Yuan, Yan</creatorcontrib><title>Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. To develop models to predict age-specific POI risk for the ages of 21–40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included. We evaluated models that used algorithms based on statistical or machine learning to consider all predictors, including cancer treatments. Cross-validated prediction performance metrics (eg, area under the receiver operating characteristic curve [AUROC]) were compared to select the best-performing models. For external validation of the models, we used data from 5-year survivors in the St Jude Lifetime Cohort (SJLIFE) with ovarian status clinically ascertained using hormone measurements (menopause defined by follicle stimulating hormone &gt;30 mIU/mL and oestradiol &lt;17 pg/mL) and medical chart or questionnaire review. We also evaluated an SJLIFE-based polygenic risk score for POI among 1985 CCSS survivors with genotype data available. 7891 female CCSS survivors (922 with POI) were included in the development of the POI risk prediction model, and 1349 female SJLIFE survivors (101 with POI) were included in the validation study. Median follow-up from cancer diagnosis was 23·7 years (IQR 18·3–30·0) in CCSS and 15·1 years (10·4–22·9) in SJLIFE. Between the ages of 21 and 40 years, POI prevalence increased from 7·9% (95% CI 7·3–8·5) to 18·6% (17·3–20·0) in CCSS and 7·3% (5·8–8·9) to 14·9% (11·6–19·1) in SJLIFE. Age-specific logistic regression models considering ovarian radiation dosimetry or prescribed pelvic and abdominal radiation dose, along with individual chemotherapy predictors, performed well in CCSS. In the SJLIFE validation, the prescribed radiation dose model performed well (AUROC 0·88–0·95), as did a simpler model that considered any exposures to pelvic or abdominal radiotherapy or alkylators (0·82–0·90). Addition of the polygenic risk predictor significantly improved the average positive predictive value (from 0·76 [95% CI 0·63–0·89] to 0·87 [0·80–0·94]; p=0·029) among CCSS survivors treated with ovarian radiation and chemotherapy. POI risk prediction models using treatment information showed robust prediction performance in adult survivors of childhood cancer. Canadian Institutes of Health Research, US National Cancer Institute.</description><subject>Abdomen</subject><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Canada</subject><subject>Cancer Survivors</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Childhood</subject><subject>Children</subject><subject>Diagnosis</subject><subject>Dosimetry</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Fertility</subject><subject>Genotypes</subject><subject>Humans</subject><subject>Medical diagnosis</subject><subject>Medical records</subject><subject>Menopause</subject><subject>Menstruation</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - therapy</subject><subject>Ovaries</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prediction models</subject><subject>Primary Ovarian Insufficiency - diagnosis</subject><subject>Primary Ovarian Insufficiency - epidemiology</subject><subject>Primary Ovarian Insufficiency - etiology</subject><subject>Questionnaires</subject><subject>Radiation therapy</subject><subject>Regression analysis</subject><subject>Reproductive status</subject><subject>Risk Factors</subject><subject>Self report</subject><subject>Statistical analysis</subject><subject>Survivor</subject><subject>Survivors</subject><subject>Transplants &amp; implants</subject><subject>Tumors</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>1470-2045</issn><issn>1474-5488</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc2O0zAUhSMEYmYKjwC6EpthEbATJ07YIFSGP1ViUVhbjn099ZDEHduJ1IflXXDTMgs2SJZsX3_n3CufLHtByRtKaP12SxkneUFYdV2UrwmpKMn5o-wylVlesaZ5vJxPyEV2FcIdIZRTUj3NLkre8qImzWX2-yPO2Lv9gGMEOWqYZW-1jNaN4AzIW8zDHpU1VoG34RfsPWqrlvfBaewDGOdT1Q7SH8DN0ls5gh3DZJLG4qgO6Qa9G2_ziH6AMPnZzs6Ho7_a2V7vnNOg5KjQvwMJHvfORzDeDRB3COsHZr0wsD07wDZO-rBMvY3wbdIIG2sw2iGJ3C6ZPMueGNkHfH7eV9nPTzc_1l_yzffPX9cfNrlijMTcKE5byhSqskJSkqZoVcm69EV1U_JK8gRg3dVMpUW50cioqdu6w5o1HZHlKrs--e69u58wRDHYoLDv5YhuCqJoWsqrglVlQl_9g965yY9puiPFkmuRmq6y6kQp70LwaMT5hwUl4pi_WPIXx3BFUYolf8GT7uXZfeoG1A-qv4En4P0JSMnhbNGLsISUQvWootDO_qfFH8MuxBY</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Im, Cindy</creator><creator>Lu, Zhe</creator><creator>Mostoufi-Moab, Sogol</creator><creator>Delaney, Angela</creator><creator>Yu, Lin</creator><creator>Baedke, Jessica L</creator><creator>Han, Yutong</creator><creator>Sapkota, Yadav</creator><creator>Yasui, Yutaka</creator><creator>Chow, Eric J</creator><creator>Howell, Rebecca M</creator><creator>Bhatia, Smita</creator><creator>Hudson, Melissa M</creator><creator>Ness, Kirsten K</creator><creator>Armstrong, Gregory T</creator><creator>Nathan, Paul C</creator><creator>Yuan, Yan</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>202312</creationdate><title>Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort</title><author>Im, Cindy ; Lu, Zhe ; Mostoufi-Moab, Sogol ; Delaney, Angela ; Yu, Lin ; Baedke, Jessica L ; Han, Yutong ; Sapkota, Yadav ; Yasui, Yutaka ; Chow, Eric J ; Howell, Rebecca M ; Bhatia, Smita ; Hudson, Melissa M ; Ness, Kirsten K ; Armstrong, Gregory T ; Nathan, Paul C ; Yuan, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-fc71914cec35e030829c34b72668375a7fc7e6b64c64c17fde41f696be648b0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Canada</topic><topic>Cancer Survivors</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Childhood</topic><topic>Children</topic><topic>Diagnosis</topic><topic>Dosimetry</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Fertility</topic><topic>Genotypes</topic><topic>Humans</topic><topic>Medical diagnosis</topic><topic>Medical records</topic><topic>Menopause</topic><topic>Menstruation</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - therapy</topic><topic>Ovaries</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prediction models</topic><topic>Primary Ovarian Insufficiency - diagnosis</topic><topic>Primary Ovarian Insufficiency - epidemiology</topic><topic>Primary Ovarian Insufficiency - etiology</topic><topic>Questionnaires</topic><topic>Radiation therapy</topic><topic>Regression analysis</topic><topic>Reproductive status</topic><topic>Risk Factors</topic><topic>Self report</topic><topic>Statistical analysis</topic><topic>Survivor</topic><topic>Survivors</topic><topic>Transplants &amp; implants</topic><topic>Tumors</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Im, Cindy</creatorcontrib><creatorcontrib>Lu, Zhe</creatorcontrib><creatorcontrib>Mostoufi-Moab, Sogol</creatorcontrib><creatorcontrib>Delaney, Angela</creatorcontrib><creatorcontrib>Yu, Lin</creatorcontrib><creatorcontrib>Baedke, Jessica L</creatorcontrib><creatorcontrib>Han, Yutong</creatorcontrib><creatorcontrib>Sapkota, Yadav</creatorcontrib><creatorcontrib>Yasui, Yutaka</creatorcontrib><creatorcontrib>Chow, Eric J</creatorcontrib><creatorcontrib>Howell, Rebecca M</creatorcontrib><creatorcontrib>Bhatia, Smita</creatorcontrib><creatorcontrib>Hudson, Melissa M</creatorcontrib><creatorcontrib>Ness, Kirsten K</creatorcontrib><creatorcontrib>Armstrong, Gregory T</creatorcontrib><creatorcontrib>Nathan, Paul C</creatorcontrib><creatorcontrib>Yuan, Yan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Im, Cindy</au><au>Lu, Zhe</au><au>Mostoufi-Moab, Sogol</au><au>Delaney, Angela</au><au>Yu, Lin</au><au>Baedke, Jessica L</au><au>Han, Yutong</au><au>Sapkota, Yadav</au><au>Yasui, Yutaka</au><au>Chow, Eric J</au><au>Howell, Rebecca M</au><au>Bhatia, Smita</au><au>Hudson, Melissa M</au><au>Ness, Kirsten K</au><au>Armstrong, Gregory T</au><au>Nathan, Paul C</au><au>Yuan, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2023-12</date><risdate>2023</risdate><volume>24</volume><issue>12</issue><spage>1434</spage><epage>1442</epage><pages>1434-1442</pages><issn>1470-2045</issn><issn>1474-5488</issn><eissn>1474-5488</eissn><abstract>Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. To develop models to predict age-specific POI risk for the ages of 21–40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included. We evaluated models that used algorithms based on statistical or machine learning to consider all predictors, including cancer treatments. Cross-validated prediction performance metrics (eg, area under the receiver operating characteristic curve [AUROC]) were compared to select the best-performing models. For external validation of the models, we used data from 5-year survivors in the St Jude Lifetime Cohort (SJLIFE) with ovarian status clinically ascertained using hormone measurements (menopause defined by follicle stimulating hormone &gt;30 mIU/mL and oestradiol &lt;17 pg/mL) and medical chart or questionnaire review. We also evaluated an SJLIFE-based polygenic risk score for POI among 1985 CCSS survivors with genotype data available. 7891 female CCSS survivors (922 with POI) were included in the development of the POI risk prediction model, and 1349 female SJLIFE survivors (101 with POI) were included in the validation study. Median follow-up from cancer diagnosis was 23·7 years (IQR 18·3–30·0) in CCSS and 15·1 years (10·4–22·9) in SJLIFE. Between the ages of 21 and 40 years, POI prevalence increased from 7·9% (95% CI 7·3–8·5) to 18·6% (17·3–20·0) in CCSS and 7·3% (5·8–8·9) to 14·9% (11·6–19·1) in SJLIFE. Age-specific logistic regression models considering ovarian radiation dosimetry or prescribed pelvic and abdominal radiation dose, along with individual chemotherapy predictors, performed well in CCSS. In the SJLIFE validation, the prescribed radiation dose model performed well (AUROC 0·88–0·95), as did a simpler model that considered any exposures to pelvic or abdominal radiotherapy or alkylators (0·82–0·90). Addition of the polygenic risk predictor significantly improved the average positive predictive value (from 0·76 [95% CI 0·63–0·89] to 0·87 [0·80–0·94]; p=0·029) among CCSS survivors treated with ovarian radiation and chemotherapy. POI risk prediction models using treatment information showed robust prediction performance in adult survivors of childhood cancer. Canadian Institutes of Health Research, US National Cancer Institute.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37972608</pmid><doi>10.1016/S1470-2045(23)00510-7</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1470-2045
ispartof The lancet oncology, 2023-12, Vol.24 (12), p.1434-1442
issn 1470-2045
1474-5488
1474-5488
language eng
recordid cdi_proquest_miscellaneous_2891752453
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Abdomen
Adult
Age
Age Factors
Canada
Cancer Survivors
Cancer therapies
Chemotherapy
Child
Childhood
Children
Diagnosis
Dosimetry
Drug dosages
Female
Fertility
Genotypes
Humans
Medical diagnosis
Medical records
Menopause
Menstruation
Neoplasms - drug therapy
Neoplasms - therapy
Ovaries
Patients
Pediatrics
Prediction models
Primary Ovarian Insufficiency - diagnosis
Primary Ovarian Insufficiency - epidemiology
Primary Ovarian Insufficiency - etiology
Questionnaires
Radiation therapy
Regression analysis
Reproductive status
Risk Factors
Self report
Statistical analysis
Survivor
Survivors
Transplants & implants
Tumors
Young Adult
Young adults
title Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A09%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20age-specific%20risk%20prediction%20models%20for%20primary%20ovarian%20insufficiency%20in%20long-term%20survivors%20of%20childhood%20cancer:%20a%20report%20from%20the%20Childhood%20Cancer%20Survivor%20Study%20and%20St%20Jude%20Lifetime%20Cohort&rft.jtitle=The%20lancet%20oncology&rft.au=Im,%20Cindy&rft.date=2023-12&rft.volume=24&rft.issue=12&rft.spage=1434&rft.epage=1442&rft.pages=1434-1442&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(23)00510-7&rft_dat=%3Cproquest_cross%3E2891752453%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2894696268&rft_id=info:pmid/37972608&rft_els_id=S1470204523005107&rfr_iscdi=true